1219086-88-0

Usage

Uses

Used in Pharmaceutical Industry:
D-Proline, 3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-, 1,1-dimethylethyl ester, (3S,4R,5S)-relis used as a reactant in the synthesis of RG7388, a potent and selective p53-MDM2 inhibitor. D-Proline, 3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-diMethylpropyl)-, 1,1-diMethylethyl ester, (3S,4R,5S)-relplays a crucial role in the development of targeted cancer therapies, as it contributes to the formation of a drug that can potentially disrupt the interaction between the p53 tumor suppressor protein and the MDM2 protein, thereby restoring the tumor suppressor function and inhibiting cancer cell growth.

Upstream product

• 85070-48-0 2-fluoro-3-chlorobenzaldehyde 
• 1219086-87-9 (Z)-3-(3-chloro-2-fluorophenyl)-2-(4-chloro-2-fluorophenyl)prop-2-enenitrile 
• 75279-53-7 2-(4-chloro-2-fluoro-phenyl)acetonitrile 
• 2987-16-8 3,3-dimethylbutyrylaldehyde 
• 6456-74-2 Glycine tert-butyl ester 
• 1219086-34-6 2-[(E)-(3,3-dimethylbutylidene)amino]acetic acid tert-butyl ester 
• 926-36-3 4,4-dimethylpentanal 

Downstream Products

• 1219089-31-2 (2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxylic acid 
• 1364614-53-8 rac-(6S,7R,8S,8aR)-8-(3-chloro-2-fluoro-phenyl)-7-(4-chloro-2-fluoro-phenyl)-2-((S)-3,4-dihydroxy-butyl)-6-(2,2-dimethyl-propyl)-1-oxo-octahydro-pyrrolo[1,2-a]pyrazine-7-carbonitrile 
• 1364616-38-5 (6R,7S,8R,8aS)-8-(3-chloro-2-fluorophenyl)-7-(4-chloro-2-fluorophenyl)-2-((S)-3,4-dihydroxybutyl)-6-(2,2-dimethylpropyl)-1-oxo-octahydropyrrolo[1,2-a]pyrazine-7-carbonitrile 
• 1219082-66-2 (2R,3R,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxylic acid ((S)-3,4-dihydroxybutyl)amide 
• 1219085-25-2 4-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino}benzoic acid t-butyl ester 
• 1219089-32-3 (2S,3R,4S,5R)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxylic acid 
• 1229704-88-4 (2R,3S,4R,5S)-4-(4-chloro-2-fluorophenyl)-3-(3-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxylic acid (5-iodopyridin-2-yl)amide 
• 1219084-26-0 (2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxylic acid [1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-3-yl]amide 
• 1229705-02-5 rac-6-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-nicotinic acid methyl ester 
• 1219085-06-9 3-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino}benzoic acid 
• 1229704-94-2 4-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino}-2-fluoro-benzoic acid tert-butyl ester 
• 1229705-05-8 4-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino}-3-methoxybenzoic acid methyl ester 
• 1219085-27-4 4-{[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino}benzoic acid 
• 1229704-87-3 6-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluorophenyl)-3-(3-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino}nicotinic acid 

Relevant academic research and scientific papers

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

Restoration of p53 activity by inhibition of the p53-MDM2 interaction has been considered an attractive approach for cancer treatment. However, the hydrophobic protein-protein interaction surface represents a significant challenge for the development of s

SUBSTITUTED HEXAHYDROPYRROLO[1,2-C]IMIDAZOLONES

There are provided compounds of formula I or a pharmaceutically acceptable salt thereof, wherein X, Y, R1, R1′, R2, R2′, R3, R4, R5 are as defined herein. The compounds exhibit a

N-SUBSTITUTED PYRROLIDINES

Compounds of formula and enantiomers and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceu

Substituted Pyrrolidine-2-Carboxamides

There are provided compounds of the formula wherein X, Y, R1, R2, R3, R3, R4, R5, R6 and R7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.